Podcasts about clinical trials

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Process innovation in the pharmaceutical industry is never easy, but its best chance of success comes when companies come together to work on big problems – especially when they bring in regulators and other stakeholders.   In today's episode of the pharmaphorum podcast, host Jonah Comstock speaks with Rob DiCicco, vice president of portfolio management at TransCelerate Biopharma, a membership organisation where big pharma companies work together to innovate around the discovery, development, and manufacturing of new drugs.   DiCicco gives an update on TransCelerate's work with pragmatic trials and the group's meetings last year with the FDA. He discusses what pragmatic trials are and how they can improve the efficiency of clinical research, as well as describing the work that was done at the meeting last year and the report that's come out of it.   He also gets into next steps, how the new administration has and hasn't affected the work TransCelerate is doing with the FDA, and the role TransCelerate plays in taking these recommendation and putting them into practice.   Tune in to learn how the pharma industry is working together to change the way clinical trials are done.

The FDA belatedly liberates women's hormone replacement; Beta-blockers now deemed passé for routine heart attack aftercare; After most breast cancer surgery, adjuvant radiation brings no survival benefits; Can you drink caffeinated coffee if you have atrial fibrillation? Ignore frequent falls without attention to balance and stability training at your peril; Is it reasonable to contemplate a knee replacement surgery at 88? 

BUFFALO, NY – November 17, 2025 – A new #research perspective was #published in Oncotarget (Volume 16) on November 14, 2025, titled “A personal perspective of patient-centred clinical trials.” In this perspective, led by corresponding author Jia Liu of The Kinghorn Cancer Centre, St Vincent's Hospital, the University of New South Wales, and the Garvan Institute of Medical Research, three early-phase clinical trial participants — Trevor Tyne, Elizabeth Ivimey, and Leanne Duggan — reflect on their personal experiences with experimental cancer treatments. Their stories offer a unique perspective on the patient journey through early-phase trials and emphasize the need to design clinical research that prioritizes patients' needs, dignity, and lived realities. The authors highlight both the life-changing opportunities that trials can provide and the systemic barriers that still prevent many patients from participating. This perspective captures a turning point in how early-phase trials are viewed. Once considered a last resort, these trials are now increasingly offered earlier in treatment, especially with the rise of biomarker-guided therapies. In this context, the patient experience has become critical. The authors outline key benefits of participation, including access to novel therapies, ongoing medical monitoring, emotional support, and a strong sense of purpose in contributing to future medical advancements. However, they also point out significant challenges, such as restrictive eligibility criteria, high financial and logistical burdens, and communication gaps between patients and trial staff. “While no trial guarantees success, the level of support, access to innovative therapies, and sense of contribution to medical progress can be profoundly meaningful.” Each narrative provides insight into the clinical trial experience. One patient explains how living with a visual impairment required tailored accessibility support throughout the trial process Another shares how genomic testing led to targeted treatment after standard options failed. Despite their different diagnoses and circumstances, all three stories reflect resilience, hope, and a shared call for trial designs that better reflect the realities of diverse patients. To address these issues, the authors propose a number of improvements to trial design and delivery. These include expanding eligibility criteria, offering financial and logistical assistance, improving communication training for research staff, and introducing dedicated trial navigators to help guide patients through complex processes. They also focus on the importance of involving patient advocates in trial design and ensuring smoother transitions for patients moving between treatment centers. While early-phase trials focus on safety and effectiveness, the authors argue they must also be guided by core values like ethics and patient empowerment. This perspective serves as a reminder that the future of cancer research depends not only on scientific innovation, but on an honest partnership between patients and the research community. By sharing these real-world experiences, the article encourages a broader conversation about how to make clinical trials more responsive to the people they are designed to serve. DOI - https://doi.org/10.18632/oncotarget.28776 Correspondence to - Jia Liu - jia.liu@svha.org.au Abstract video - https://www.youtube.com/watch?v=2CCGN78n8ug To learn more about Oncotarget, visit https://www.oncotarget.com: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

The Spiders briefly discuss Clinical Trials, Violet Lucca's scholarly analysis of David Cronenberg's filmography, focusing primarily on the downsides of theory-oriented analysis, then go into more depth on the relationship between Cronenberg's new film The Shrouds and his earlier work Naked Lunch.

Featuring perspectives from Dr Jeremy S Abramson and Dr Manali Kamdar, including the following topics:  Introduction: About This Program (0:00) Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (3:10) Potential Treatment Benefits of CAR T-Cell Therapy (10:35) CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) (34:32) Finding Information About CAR T; Clinical Trials (42:17) Financial Issues; Risk of Infection (48:11) Coping with Anxiety; Healing and Moving On (55:17) Educational and presenter information

The Foundation funded preclinical studies for the approach and launched Opus.

Biochemist Lingyin Li survived breast cancer at just 30 and now works to harness the human immune system to fight cancers that have long evaded treatment. T cells, she says, are powerful cancer killers, but they can be oblivious. She and her lab colleagues have discovered a masking enzyme that squelches the immune system's “danger signals” and are now developing drugs to block that enzyme. She likens her work to an arms race between cancer and immunotherapy. “The cancers are not getting smarter, but we are,” Li tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Lingyin LiConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Lingyin Li, a professor of biochemistry at Stanford University.(00:03:38) Research MotivationLingyin explains how her breast cancer diagnosis inspired her research.(00:04:31) How T-Cells WorkT-cell mechanisms and why they struggle to reach solid tumors.(00:05:38) Immune System OverviewInnate and adaptive immunity and how mutations make cancer recognizable.(00:07:28) Awakening the Immune SystemEfforts to stimulate innate immune cells to detect and expose tumors.(00:10:54) The Cancer SignalDiscovery of cancer-derived DNA signals that alert the immune system.(00:13:01) Cancer's Evasion MechanismHow tumors destroy immune signals to hide from detection.(00:14:26) ENPP1 EnzymeIdentification of ENPP1 as the enzyme enabling immune evasion.(00:15:22) Balancing Immunity and SafetyRole of ENPP1 in autoimmunity and the challenge of targeting it safely.(00:19:30) ENPP1 InhibitorsDevelopment of molecules to block ENPP1 and enhance immune signaling.(00:24:55) Preclinical FindingsThe promising results against aggressive solid tumors in animal studies(00:28:05) From Lab to ClinicThe progress toward FDA approval and preparation for human testing.(00:31:04) Future In a MinuteRapid-fire Q&A: innovation, collaboration, and the outlook for cancer treatment.(00:33:14) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this Huberman Lab Essentials episode, my guest is Dr. Jack Feldman, PhD, a Distinguished Professor of Neurobiology at the University of California, Los Angeles, and a leading expert in the science of breathing. We explain the mechanics of breathing and the neural circuits that generate and regulate our breathing rhythm. We also discuss how breathing patterns profoundly influence mental states, including their role in reducing anxiety and enhancing emotional resilience. Dr. Feldman also shares practical tools, such as box breathing for daily performance and magnesium L-threonate supplementation to support cognitive health and longevity. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman Mateina: https://drinkmateina.com/huberman Eight Sleep: https://eightsleep.com/huberman Timestamps 00:00:00 Jack Feldman 00:00:23 Breathing Mechanics, Diaphragm; Pre-Bötzinger Complex & Breath Initiation 00:03:25 Nose vs Mouth Breathing 00:04:23 Sponsor: Mateina 00:05:24 Active Expiration & Brain; Retrotrapezoid Nucleus 00:08:32 Diaphragm & Evolution; Lung Surface Area & Alveoli, Oxygen Exchange 00:12:56 Diaphragmatic vs Non-Diaphragmatic Breathing 00:14:23 Physiological Sighs: Frequency & Function; Polio & Ventilators 00:18:21 Sponsor: AGZ by AG1 00:19:52 Drug Overdose, Death & Gasps 00:21:38 Meditation, Slow Breathing & Fear Conditioning Study 00:25:28 Mechanistic Science in Breathwork Validation; Breath Practice & Reduced Fear 00:27:21 Breathing & Emotional/Cognitive State, Olfaction, Vagus Nerve 00:29:44 Carbon Dioxide, Hyperventilation & Anxiety 00:31:21 Sponsor: Eight Sleep 00:32:47 Breathing, Emotion & Autonomic Processes Coordination; Depression & Breath Practices 00:36:43 Tool: Breathwork Practices, Box Breathing, Tummo, Wim Hof 00:38:46 Magnesium L-Threonate & Cognitive Enhancement; Compound Refinement 00:44:28 Clinical Trial, Magnesium L-Threonate & Cognitive Improvements; Dose, Sleep 00:48:28 Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Love the episode? Send us a text!Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast CancerIn this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what's new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option.Dr. Layman walks us through the VIKTORIA-1 trial, a phase III study of a new IV drug (genitolasib, “G” for short) that targets the PAM pathway, which cancer cells often use to grow and outsmart standard hormone therapy. She explains, in plain language, what PIC3CA mutations are, what “wild-type” means, and why this trial is so exciting even for people without a PIC3CA mutation.You'll hear:Why ER-positive breast cancer is the most common subtype—and still a major driver of metastatic diseaseHow clinical trials are designed, and why they're often most powerful earlier in treatment (not only when “nothing else is left”)A clear explanation of the VIKTORIA-1 study design: who was eligible, how the drug is given, and what the results showedWhat “progression-free survival” means and how adding “G” changed the numbers compared to standard therapy aloneHonest talk about side effects (mouth sores, rash, blood sugar changes), and how teams are preventing and managing themHow patients can look up trials like VIKTORIA-1 and VIKTORIA-2 on ClinicalTrials.gov and bring these conversations back to their own oncologistsWhether you're living with ER-positive metastatic breast cancer, supporting someone who is, or simply trying to understand the rapidly evolving science, this episode offers both education and hope.Support the showLatest News: Become a Breast Cancer Conversations+ Member! Sign Up Now. Join our Mailing List - New content drops every Monday!

Can your chatbot tell when you're spiraling, or does it just play along?In this episode of Your AI Injection, host Deep Dhillon sits down with Dr. Grin Lord, clinical psychologist and Founder/CEO of mpathic, to explore what happens when empathic AI meets real human vulnerability. Grin explains how a single 15-minute session of empathic listening in an ER setting led to massive drops in repeat drunk-driving incidents and billions in healthcare savings, and why that same science now underpins AI models that analyze clinician–patient conversations. The two dig into how mpathic trains and validates models that can flag suicide risk, psychosis, and protocol deviations in high-stakes clinical trials, all while keeping a human in the loop. They also unpack a looming dilemma: as foundation models become eerily “good listeners,” will people prefer bots to friends and therapists? What harms emerge when AI politely reflects back someone's delusions? Tune in to hear how psychologists are reshaping AI safety, and why your favorite assistant may soon be better at detecting crises than your closest human relationships.Learn more about Grin here: https://www.linkedin.com/in/grinlord/and mpathic here: https://www.mpathic.aiCheck out our related episodes:Can Humanoid Robots Save Us from Loneliness? The Promise and Peril of Empathetic AI with Niv Sundaram of Machani RoboticsIs AI the Missing Ingredient for Curbing Cravings? Emotional Eating Meets Machine Learning with Dr. Sera LavelleCan AI Spot Diseases Your Doctor Might Miss? The Machine That Never Gets Tired with RJ Kedziora of Estenda Solutions

Join host and Digital Education Committee Member Sandeep A Saha, MD, MS, FHRS for this lively discussion with his colleagues Charles A. Henrikson, MD, MPH, FHRS and Arun R. Mahankali Sridhar, MBBS, MPH, FACC. About this Article: In patients with symptomatic premature ventricular complexes (PVCs) refractory to medical therapy, non-invasive low-level tragus stimulation of the auricular branch of the vagus nerve significantly reduced median PVC burden compared to sham stimulation (median reduction ~13.4% vs ~8.6%; P = 0.021). The findings suggest that autonomic neuromodulation via transcutaneous vagal stimulation may offer a novel adjunctive therapy for frequent PVCs, although further larger trials are needed to evaluate long-term outcomes. Learning Objectives Describe the rationale and mechanism by which transcutaneous vagus nerve stimulation (tVNS) may modulate autonomic tone and reduce premature ventricular contractions. Summarize the design, methods, and key outcomes of the NoVa-PVC randomized crossover trial evaluating tVNS for symptomatic PVC reduction. Evaluate the clinical implications, limitations, and potential future applications of noninvasive neuromodulation as a therapeutic approach for ventricular arrhythmias. Article Authors Stefanos Zafeiropoulos MD, MBA, Kristie Coleman MPH, RN, Jonathan Kogan,Dimitrios Varrias MD, Jonas Leavitt BS, Alexandra Bekiaridou MD, Theodoros Zanos PhD, Stavros Zanos PhD, MD, Stavros Stavrakis PhD, MD, Stavros Mountantonakis MD, MBA  Podcast Contributors Sandeep A Saha, MD, MS, FHRS Charles A. Henrikson, MD, MPH, FHRS Arun R. Mahankali Sridhar, MBBS, MPH, FACC  All relevant financial relationships have been mitigated. Host Disclosure(s): S. Saha •Speaking/Teaching/Consulting: Medtronic   ​Contributor Disclosure(s):    C. Henrikson •Honoraria/Speaking/Teaching/Consulting: American College of Cardiology A. Sridhar •Nothing to disclose.   Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.

What does it really take to challenge the status quo, fight for truth, and defend your values in a system built to silence dissent?For Aaron Siri, attorney and advocate, it began in courtrooms and regulatory filings, standing up for parental rights, informed consent, and transparent systems, even when the odds were stacked against him. Today, he navigates litigation, policy, and public trust in one of the most contentious debates of our time: vaccines.In this episode of Common Denominator, we unpack Aaron's journey from legal underdog to vocal defender of transparency, how he analyzes systems most ignore, and why courage isn't loud, it's consistent.In this episode, you'll learn:- What it looks like when regulatory systems prioritize power over process- Why informed consent and transparency matter more today than ever- The mindset shifts required to challenge conventional wisdom and speak truth to power- How to stay true to your values when pressure to conform is constant- What freedom of speech really means when you're up against the establishmentLike this episode? Leave a review here: https://ratethispodcast.com/commondenominatorLearn more about Aaron Siri: Siri & Glimstad Law Firm: https://www.sirillp.com/aaron-siri/Book: "Vaccines, Amen: The Religion of Vaccines" https://www.amazon.com/stores/author/B0FQ4JMV3M

Send us a textDr. Evan Loh joins Dr. Michael Koren to discuss Dr. Loh's journey through the medical profession. Dr. Loh moved from doing lab work in medical school to patient care in the academic sphere and into the pharmaceutical world of research. Dr. Loh and Dr. Koren discuss the core differences between bedside physican work and research, including in time spent with patients, physician incentives, and the treatment that results. Through it all the doctors find a simple axiom: all medicine is about patients at the end of the day.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Pre-Order The Forever Strong PLAYBOOK and receive exclusive bonuses: https://drgabriellelyon.com/playbook/Want ad-free episodes, exclusives and access to community Q&As? Subscribe to Forever Strong Insider: https://foreverstrong.supercast.comIn this fascinating episode, Dr. Gabrielle Lyon talks with neuroscientist Dr. Ben Rein, PhD (author of Why Brains Need Friends), about the science of social connection, emotion, and cognitive health. Dr. Rein, an expert in neurobiology and psychedelic research, reveals the cutting-edge studies that explain why loneliness is as damaging as smoking and how our digital world is affecting our brain's ability to connect.They discuss the neurochemistry of love, the controversial use of MDMA in therapy, and whether AI can ever truly replace human intimacy. This conversation provides an essential look at the biological drivers of happiness, performance, and long-term brain health.Chapter Markers:0:00 - MDMA (Molly): The History & Therapeutic Benefits 5:59 - The Legal Status of MDMA for PTSD 6:44 - The Safety and Effectiveness of MDMA in Clinical Trials 8:29 - PTSD (The Amygdala Alarm) 9:41 - How MDMA Soothes the Amygdala to Access Memory 11:42 - Is There an Alternative to MDMA? (Ketamine's Mechanism) 13:16 - Ketamine and Neuroplasticity for Depression 15:48 - Botox and Empathy: 18:12 - The Problem of Volume: How Screens Depersonalize Interaction 19:48 - The Virtual Disengagement Hypothesis Explained 25:00 - Defining Cognitive and Emotional Empathy 29:43 - MDMA's Link to Serotonin & Social Reward 31:04 - Do SSRIs Have Pro-Social Effects? 36:10 - The Science of Likability and "Easy to Read" Faces 40:10 - Top 3 Ways to Be More Likable49:49 - The Likability Gap: Why You Underestimate How Well-Liked You Are 56:59 - The Neurobiology of Oxytocin, Dopamine, and Serotonin1:09:23 - The Goldilocks Zone of Empathy 1:15:58 - Narcolepsy 1:18:16 - Alcohol: Why the Neurotoxin is Bad for Brain Health 1:21:47 - Exercise and Neurogenesis1:22:27 - Sex, Orgasm, and Oxytocin Release 1:25:06 - Oxytocin During Childbirth Who is Ben Rein:Dr. Ben Rein is an award-winning neuroscientist and Chief Science Officer of the Mind Science Foundation, where he supports early-career researchers in neuroscience. He earned his PhD from SUNY Buffalo and completed postdoctoral training at Stanford University, publishing over 20 peer-reviewed papers on autism, empathy, MDMA, and digital behavior. Recognized by the NIH, the Society for Neuroscience, and Sigma Xi, he also serves as a scientific advisor to more than 20 organizations. With over one million followers and 75 million video views, Dr. Rein is celebrated for making neuroscience accessible to the public and has been featured by outlets such as Good Morning America, ABC News, and PopularMechanics.Thank you to our sponsors:BodyHealth: Use code LYON20 to get 20% off your first order https://www.bodyhealthaffiliates.com/73L4QL3/7XDN2/BON CHARGE Holiday Sale https://boncharge.com for 25% off Pique 20% off for life: https://Piquelife.com/DRLYONFind Ben Rein at: Website: https://www.benrein.com/Instagram: https://www.instagram.com/dr.benrein/#TikTok: https://www.tiktok.com/@dr.benrein?lang=enFacebook:

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Drs. Kat Talcott and Sarwar Zahid join to discuss the December 2025 edition of Retinal Physician, including an overview of TKIs for retinal disease, the fluorinated gas and sustainability question, best practices for research clinical trial sites, and fellowship selection advice.

Just 4 simple lifestyle measures deliver 9 additional years of disease-free healthspan; Study underscores protein's role in staving off cancer, heart disease, and death; CoQ10 scores vs. neurodegeneration; Urolithin A (Mitopure®️) found to support athletic performance, immune function; Why you should ignore some influencers' advice to avoid fish oil. 

Send us a textDr. Koren joins Kevin Geddings to report live from the American Heart Association meeting in New Orleans with fresh results on LDL lowering, prevention, and the future of gene editing for cholesterol. They discuss the excitement of big meetings like the AHA and how results can even surprise the investigators that were working on a study.Note: Dr. Koren refers to CRISPR Therapeutics, a company developing gene-based cholesterol lowering technologies. CRISPR-Cas9 is also the general name of a gene editing technique.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textCould exercise be just what the doctor ordered for recovery during chemotherapy? In this episode of “The UMB Pulse,” explore this novel approach to cancer recovery with Ian Kleckner, PhD, MPH, associate professor at the University of Maryland School of Nursing and director of the SYNAPSE Center. Kleckner shares how exercise can alleviate symptoms of chemotherapy-induced peripheral neuropathy and improve the quality of life for cancer survivors. Through his research, Kleckner investigates how movement can reduce inflammation, enhance brain and body coordination, and empower patients to reclaim their lives. Chapter Markers 00:00 – Introduction 00:00:17 – Cancer Treatment & Neuropathy 00:01:37 – Guest Introduction: Dr. Ian Kleckner 00:05:06 – Understanding Neuropathy 00:09:38 – Research Findings: Brain & Exercise 00:13:33 – Exercise Intervention & Clinical Trials 00:19:08 – Practical Advice & Takeaways 00:23:31 – Conclusion & CreditsListen to The UMB Pulse on Apple, Spotify, Amazon Music, and wherever you like to listen. The UMB Pulse is also now on YouTube.Visit our website at umaryland.edu/pulse or email us at umbpulse@umaryland.edu.

Kidney Week has begun. Listen as Hiddo Jan L. Heerspink, PhD, Julie R. Ingelfinger, MD, and Richard A. Lafayette, MD, explore the impact this year's late-breaking clinical trials will have on nephrology.

Kidney Week has begun. Listen as Hiddo Jan L. Heerspink, PhD, Julie R. Ingelfinger, MD, and Richard A. Lafayette, MD, explore the impact this year's late-breaking clinical trials will have on nephrology.

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This conversation features insights from Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII. Our guests continue their discussion on how autoinjectors and smart technologies can be integrated into clinical trials in a way that isn't problematic or burdensome for patients, particularly for patients that may not be tech savvy. They discuss that by focusing on patient experience, clinical trials can increase engagement and compliance.This episode is presented in partnership with ⁠PII⁠.Host⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestsOliver Eden, Senior Business Unit Director, JabilTravis Webb, Chief Scientific Officer, PIIDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

In this episode, Jonathan Sackier speaks with Brian Rini, Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA, and an internationally known leader in genitourinary oncology. The discussion explores the evolution of kidney cancer treatment, highlighting breakthroughs in immunotherapy, targeted therapy, and precision oncology. Rini shares insights from landmark clinical trials, his passion for translational research, and the challenges of broadening trial access. He also reflects on the future of the field, including the role of artificial intelligence, biomarker-driven strategies, and his hopes for advancing patient outcomes worldwide.  Timestamps:    00:00 – Introduction  01:10 – Key insights into kidney cancer  03:50 – Brian's career journey  07:40 – One piece of career advice   10:40 – Diagnosis of kidney cancer   12:04 – Treatment landscape for kidney cancer  17:00 – Landmark trials in renal cell carcinoma   19:18 – Precision-based approach in trial design and selection  23:40 – Translational research  26:35 – Clinical trial recruitment  30:25 – Diversity in kidney cancer research  32:27 – ESMO 2025 highlights  35:00 – Potential of AI in trial design and recruitment  36:43 – Uncovered areas for research  38:12 – Brian's three wishes for healthcare   

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Taking a photo of your food and getting an accurate carb count seemed like a pipe dream just a few years ago, but this week's guest says it's here. Snaq wants to help you get nutritional info, and then see how that food actually affects blood glucose, thanks to integrations with CGMs, insulin pumps, and activity trackers. Snaq founder Aurelian Briner explains how his wife's type 1 diagnosis inspired the company, how it all works (and who owns the data), and what's next. Learn more about Snaq here Clinical Trial with Snaq here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

This week on Taking The Pulse, Heather and Seth record at the NCLifeSci 2025 Annual Meeting with Sophia McLeod, Advocacy Advisor at ACRO, or the Association of Clinical Research Organizations. Sophia shares how ACRO is working with Congress and the FDA to shape the future of clinical trials, advocating for safe, ethical, and high-quality research so patients can benefit from new treatment and therapies. We explore the challenges of regulatory uncertainty, the importance of trust and transparency in AI adoption, and how ACRO's member organizations are already using AI to accelerate patient recruitment and improve trial outcomes. Listen now!

Send us a textDr. Michael Koren joins Kevin Geddings to discuss the current state of COVID vaccines and research. The cardiologist weighs the real risks and benefits of COVID vaccines, focusing on who may need protection the most and who might be able to skip this year's booster. Dr. Koren also talks about the new prescription mandate for COVID vaccines, and how joining a clinical trial may help some people clear that burden more easily.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

For TriloTalk episode 38, Lisa Chamberlain James, Senior Partner at Trilogy, and Sudipta Chakraborty, Head of Literacy & Plain Language Center of Excellence at Biogen, talk about how to use AI in the creation of lay summaries of clinical trial results. Scalability, change management, prompting, biases, realistic attitudes, and human involvement are all touched on so listen up! 

On this episode Gil Bashe and Gregg Masters sit with Joseph Dustin, founder and principal of Dauntless E-Clinical Strategies and former Medidata executive. Dustin recounts his two-decade journey transforming clinical trials—from the dawn of electronic data capture to the age of AI-driven design—and reflects on lessons learned from the late Medidata co-founder Glenn de Vries. They explore how empathy, creativity, and human connection drive innovation in clinical research—especially as artificial intelligence reshapes trial design, digital biomarkers, and decentralized models. Dustin argues that technology succeeds only when it amplifies human insight rather than replaces it. Recorded ahead of the CNS Summit 2025, the conversation highlights community, mentorship, and the “game-on” mindset that propels the next generation of biotech and mid-market innovators. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this powerful and eye-opening conversation, Leanne Woehlke sits down with Dr. Ruchir Gupta, a double board-certified pain specialist and founder of Mountain View Headache and Spine Institute, to explore the evolving world of chronic pain treatment and clinical research.Dr. Gupta shares his journey from anesthesiology into chronic pain medicine and research, highlighting why traditional approaches often fail and how emerging therapies like ketamine infusions and stem cell treatments offer new hope. Together, they discuss the importance of changing the language around "experimental" medicine, improving access to clinical trials, and educating patients and physicians about cutting-edge but underutilized treatments.They also tackle:The broken incentives in insurance-driven medicineHow to ethically introduce new treatments to patientsThe power of AI and EMRs in revolutionizing clinical trial recruitmentRebuilding trust in the medical system through transparency and educationThis episode is a must-listen for healthcare professionals, clinical researchers, and patients seeking alternatives to outdated treatments and a deeper understanding of how clinical research can drive real change in patient care.Dr Ruchir Gupta:Dr. Ruchir Gupta is a board-certified pain specialist and anesthesiologist with advanced training in chronic pain management from the Mayo Clinic's Alix School of Medicine in Arizona. A New York native, he completed medical school at Upstate Medical University in Syracuse and his anesthesiology residency at New York Medical College – St. Vincent's Hospital in Manhattan.With over 20 peer-reviewed publications and two medical textbooks to his name, Dr. Gupta blends cutting-edge Western medicine with holistic, nature-based therapies. His areas of expertise include interventional pain management, IV infusion therapy, bone marrow concentrate procedures, and regenerative orthopedics.Dr. Gupta is a member of several leading professional societies, including the American Society of Pain and Neuroscience and the American Headache Society. He currently practices in Mesa and Phoenix, Arizona, where he is also part of the elite Regenexx network of interventional orthopedic physicians.To connect with Dr Gupta:LinkedIn: https://www.linkedin.com/in/ruchir-gupta-3187326b/https://mountainviewheadacheandspine.com/

Bonnie Tinder is the founder and CEO of Raven Intelligence, an independent B2B peer review site that amplifies the voice of the customer. She focuses on software customers, consulting partners, and software vendors and helps identify the best partners for their needs. In this episode, she shares powerful insights from leading organizations on how AI is being used not to replace employees, but to enhance experiences, streamline operations, and drive better business outcomes through purpose-driven, human-centered deployment strategies.Episode 56 | Human-Centered AI StrategiesThe Big Themes:Augments, Not Replaces Humans: AI should enhance the human experience, not eliminate it. Real-world examples, such as Marriott's use of AI to improve the check-in process, demonstrate that AI can remove operational friction and allow frontline staff to focus on hospitality and customer engagement. In the energy sector, utilities are embedding AI into safety systems to make work more accurate and proactive. These examples show that the most successful AI deployments begin by identifying pain points in human workflows.Cultural Readiness Is Crucial for AI Success: AI adoption is not just a technical project; it is a cultural transformation. Multiple examples made it clear that even the most advanced tools can fail without the right introduction. One university CHRO compared AI implementation to sneaking vegetables into meals. By avoiding technical jargon and focusing on small improvements, they saw stronger adoption. People often resist what they do not understand, especially when it feels like a threat. Leaders who frame AI as a tool for reducing stress, reclaiming time, and increasing impact are more likely to succeed.AI Should Start with Outcomes: Real AI value begins with the business goal, not the technology itself. Companies that succeed with AI are the ones that begin by identifying the result they want to achieve. Whether it's streamlining hotel check-ins, reducing safety risks in energy infrastructure, or accelerating clinical breakthroughs, effective strategies start with specific problems. These companies ask their teams where the friction lies, and then choose tools to fix those issues. This is a shift from a technology-first mindset to an outcome-first mindset.The Big Quote: “I hope you know business people will all start to get to the point of like, yes, the nature of work is going to change. But AI is not going to spell doom and gloom for every worker on Earth. It's going to give many, many, many of them an opportunity to do better things." Visit Cloud Wars for more.

Send us a textUrologist Dr. Yaw Nyame joins Dr. Michael Koren to discuss bladder and prostate cancers. Dr. Nyame talks about his journey through college - including the choice between rock stardom and medical school - and how he got to the Fred Hutch Cancer Center in Seattle. Dr. Nyame explains symptoms, the history, and treatments for prostate and bladder cancer. He tells us "if you have blood in the urine, you definitely want to get to your primary care doctor." He also expands on gaps in cancer outcomes for Black men. Along the way, we weigh benefits and harms of PSA screening and talk honestly about sexual health after treatment.Show Note: Lynch syndrome is a genetic condition also known as hereditary nonpolyposis colorectal cancer (HNPCC). It represents an increased risk of several cancers, including colorectal, endometrial, gastric, ovarian, and pancreatic cancer. It is caused by an error in the DNA mismatch repair mechanism, which normally corrects for random insertions into the DNA code.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Scott Bradley, VP of AI and Innovation at Novartis. As the eighth largest pharmaceutical company in the world by revenue, Novartis' medicines reach millions of people worldwide. Their focus on the discovery and development of novel, breakthrough treatments sees them reimagining not just the delivery of said treatments, but the practice of medicine at large. Scott joins Emerj Editorial Director Matthew DeMello to examine how artificial intelligence is transforming trial design, operations, and patient engagement — while also reshaping industry trust and accountability. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

John Spink, Ph.D. is the Director and Lead Instructor for the Food Fraud Prevention Academy, as well as an Assistant Professor in the Department of Supply Chain Management (SCM) in the College of Business at Michigan State University (MSU). His food fraud prevention research focuses on policy and strategy to understand and prevent supply chain disruptions and to implement procurement best practices. He is widely published in leading academic journals and has helped lead national and global regulatory and standards activity. More recently, his teaching and research has expanded to supply chain disruption management and procurement best practices. Roy Fenoff, Ph.D. is an Associate Professor in the Department of Criminal Justice at The Military College of South Carolina (The Citadel). He is also a Forensic Handwriting and Document Examiner and an expert in forgery detection. Dr. Fenoff specializes in forgery and document fraud, food fraud and protection, and transnational crime. In this episode of Food Safety Matters, we speak with Drs. Spink and Fenoff [33:30] about: Their recurring workshop and certificate course for the annual Food Safety Summit on food fraud prevention What makes food fraud an urgent and misunderstood issue The intersections between food safety and food fraud Different ways to check for, catch, and trace food fraud The elements of a comprehensive food fraud vulnerability assessment Focus areas for companies trying to develop a deep enough understanding of their supply chains and end products to prevent food fraud from occurring How to implement a food fraud prevention strategy and management system, which is taught during Drs. Spink and Fenoff's annual Food Safety Summit course, and how course participants respond to and have applied these teachings within their companies What Drs. Spink and Fenoff find both meaningful and challenging about their food fraud prevention and research work. News and Resources News Color Manufacturers Sue West Virginia Over 'Unconstitutional' Food Dye Ban [7:08] California Enacts Law Defining Ultra-Processed Foods, Will Ban UPFs in Schools [14:40] Reagan-Udall Report Explores Strengthening Cross-Sector Responses to Food Safety Threats [23:09] Novel Salmonella Vaccine Shows Promise in Clinical Trial [28:57] Resources "Ultraprocessed Nation" in the New York Times' October 20, 2025 "The Morning" newsletter We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com

The approach may provide better visual acuity than current optogenetic therapies in clinical trials.

While we're making progress in TREATING cancer, worldwide cancer INCIDENCE is soaring, especially among young people; New guidelines for colon cancer screening urge earlier start at age 45; Rates of peanut allergy are declining as more parents follow revised advice to introduce nuts earlier to kids; What's with all the buzz about methylene blue? Legalization and stronger pot are creating an epidemic of ER visits for uncontrolled vomiting, debilitating abdominal pain; New smart toilet gives you a report card on your poop; When Zoloft doesn't work for anxiety.

Drs. Lynce and Waks discuss advances in early-stage HER2+ breast cancer, focusing on how targeted therapies have transformed outcomes. They explore de-escalation strategies, the role of platinum drugs, insights from the COMPASS trial, and the importance of pathologic complete response in guiding treatment decisions.

Dr. Nicole Glaser is the Chief of Pediatric Endocrinology and a professor of Pediatrics at UC Davis Children's Hospital. She is recognized as an international expert in pediatric diabetic ketoacidosis (DKA), an important complication of diabetes in children. She has led many of the key multi-center studies that guide DKA management. She has also been involved in the development of several national and international guidelines for DKA management in children that guide current practice worldwide.Learning Objectives:By the end of this podcast, listeners should be able to:Describe best practices for triaging patients with DKAExplain the pathophysiology of acute cerebral edema in DKADescribe the evidence and physiologic basis for fluid selection and rate in DKA Describe the evidence supporting insulin infusion rates in pediatric DKA List best practices for lab monitoring in DKA, and how to define when a patient is ready for transition to subcutaneous insulin References: Abramo TJ, Szlam S, Hargrave H, Harris ZL, Williams A, Meredith M, Hedrick M, Hu Z, Nick T, Gonzalez CV. Bihemispheric Cerebral Oximetry Monitoring's Functionality in Suspected Cerebral Edema Diabetic Ketoacidosis With Therapeutic 3% Hyperosmolar Therapy in a Pediatric Emergency Department. Pediatr Emerg Care. 2022 Feb 1;38(2):e511-e518. doi: 10.1097/PEC.0000000000001774. PMID: 30964851.Kuppermann N, Ghetti S, Schunk J, et al. Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis. N Engl J Med. 2018;378:2275-2287.Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. N Engl J Med. 2001;344:264-269.Bergmann KR, Abuzzahab MJ, Perepelista V, Udeogu J, Qiu L, Lammers S, Nickel A, Watson D, Kharbanda A. Improving Emergency Department Care for Children With Medium- and High-Risk Diabetic Ketoacidosis. Pediatrics. 2025 Oct 1;156(4):e2024068959. doi: 10.1542/peds.2024-068959. PMID: 40907982.UC-Davis-Health-Magazine-Fall-2019.pdfQuestions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Send us a textCardiologist Dr. Koren joins Kevin Geddings to talk about the importance of understanding what we know about patients. The cardiologist recounts a recently recorded podcast where he - with full consent - reviewed the cardiovascular infomation of a patient to give a broader understanding of what all of the numbers mean and how they can give doctors and patients insight into what's going on. Dr. Koren then makes an offer to do this for other patients to help illuminate other medical areas with experts in those fields - right here on MedEvidence!Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textNebulized nitroglycerin as an adjuvant drug in management of persistent pulmonary hypertension of newborns: a randomized controlled trial.Farag MM, Ghazal HAE, Abdel-Mohsen AM, Rezk MA.Eur J Pediatr. 2025 Sep 1;184(9):586. doi: 10.1007/s00431-025-06381-5.PMID: 40888971 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Leyla Muedin, a registered dietitian nutritionist, discusses the gastrointestinal (GI) side effects commonly experienced by patients using GLP-1 medications such as Ozempic and Rybelsus. Leyla introduces a nutraceutical called Digexin, created by N-X-T-U-S-A, which has shown promise in mitigating these side effects and improving overall well-being. The episode highlights the need for patients to prioritize animal protein intake and incorporate strength training to maintain muscle mass, especially when taking GLP-1 medications. Leyla emphasizes the importance of developing healthy habits and lifestyle changes to sustain weight loss after discontinuing these drugs.

In this episode of the Flex Diet Podcast, I'm joined by Erin Silver Lee, the CEO of Flow Neuroscience. We dig into some seriously cool stuff — including Flow's recent acquisition of the Halo device, which uses non-invasive brain stimulation (TDCS) to boost both athletic and mental performance.Erin and I talk about how this tech works, what the current research says, and how it's being applied to improve focus, sleep, neuroplasticity, and overall brain health. We also get into the real-world side of things — from navigating FDA regulations to running clinical trials and shaping the future of personalized brain optimization.If you're curious about where neuroscience meets performance — and how safe, evidence-based brain stimulation might fit into the next generation of recovery and training tools — you'll want to check this one out.Sponsors:Beyond Power Voltra 1: https://www.beyond-power.com/michael13Tecton Ketone Esters: https://tectonketones.comAvailable now:Grab a copy of the Triphasic Training II book I co-wrote with Cal Deitz here.Episode Chapters:00:38 Background on Halo Device and Flow Neuroscience01:50 Acquisition and Technology Insights02:09 FDA Regulation and Consumer Approval06:02 New Device Focus and User Benefits07:29 Device Design and Usage08:45 Impact on Sleep and Mental Performance16:17 Personalization and Future Developments26:06 Focus and Concentration Benefits29:33 Navigating FDA Regulations30:35 Depression Treatment Success in Europe30:51 Challenges with Regulatory Approval31:50 Real-World Success and Halo Product Launch33:23 Navigating FDA Approval and Bias42:45 Clinical Trials and Expanding Indications51:25 Brain Health and Personal Practices55:33 Podcast Conclusion and Listener Information Flex Diet Podcasts You May Enjoy: Episode 346: From Navy SEAL to Neuroscience: Dr. Blaine Lints on Ibogaine and PerformanceYouTube: https://youtu.be/8UNGgyqBWm0 Episode 241: A New Perspective on Brain Health with Dr. Shaun KornfeldYouTube: https://youtu.be/1HcgPp6Wz7QConnect with Flow Neuroscience:Website: https://www.haloneuroscience.com/Facebook: https://www.facebook.com/halo.neuroscienceYouTube: https://www.youtube.com/@HaloNeuroscienceLinkedIn: https://www.linkedin.com/company/halo-neuroscience/Instagram: https://www.instagram.com/halo.neuro/Get In Touch with Dr Mike:Instagram: DrmiketnelsonYouTube: @flexdietcertEmail: Miketnelson.com/contact-us

Clinician-scientist Jill Helms is an expert on healing. Until about age 30, people heal easily, she says, but later on, not so well. Regenerative medicine suggests avenues for improvement, she promises. Her research focuses on understanding the physical and molecular processes of healing to design better therapies. One approach awakens “sleeper” stem cells to aid healing, a new drug in trial regenerates bone, and another avenue targets infections that appear near medical devices using gum-like tissues that create sealing barriers. In many ways, nature remains our best model for healing, Helms tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Jill HelmsConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Jill Helms, a professor of surgery at Stanford University.(00:03:42) Why Study Wound HealingJill shares what led her to explore how the body repairs itself after injury.(00:04:23) How Healing WorksExplanation of physical signals, stem cells, and the stages of tissue repair.(00:07:23) Healing Declines with AgeHow healing quality and speed drop significantly after age thirty.(00:10:48) Physical vs. Biological SignalsThe biological and physical signals that work together to guide healing.(00:13:21) Regenerative MedicineTherapies designed to restore healing capacity and accelerate repair.(00:16:55) Infection and ImplantsChallenges of preventing infections around skin penetrating medical devices.(00:21:54) Nature's BlueprintUsing biological models to inspire self-renewing wound interfaces.(00:26:19)  Biomimicry and Evolutionary InsightWhat scientists are learning from animals to inform human tissue repair.(00:30:51) Future In a MinuteRapid-fire Q&A: scientific curiosity, young researchers, and supportive environments.(00:33:04) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, I'm joined by Dr. Burhan Chaudhry, MS neurologist and clinical lead at Bristol Myers Squibb, to discuss CAR-T cell therapy which is an innovative treatment currently enrolling in clinical trials for multiple sclerosis (MS). We dive into how CAR-T cell therapy targets B cells within the central nervous system, offering hope for both relapsing and progressive MS. Dr. Chaudhry explains what sets CAR-T apart from traditional disease modifying therapies, how to get involved in MS clinical trials, and what participants can expect throughout the process. Whether you're newly diagnosed or living with MS for years, join us for empowering strategies, expert advice, and the latest updates on breakthroughs in MS treatment! Bio on Burhan Chaudry: Dr. Burhan Chaudhry is a MS neurologist and clinical lead at Bristol Myers Squibb. His sister was diagnosed with MS when he was in medical school. This inspired him to pursue Neurology. A few years after Burhan was diagnosed with MS as well. After becoming a MS neurologist, Burhan has treated MS patients both in the US and internationally. He is currently clinical lead for a global clinical trial evaluating a novel cell therapy across the MS spectrum. Resources mentioned in this episode: Website to view CAR-T info: https://www.cartautoimmune.com/ ECTRIMS 2025 Results/Report: https://distribute.congrex.com/from.storage?image=rqetJOF1YXChDh_STAPoNpjPhysyG76sohBKnHJhR-TsF3Mvxzx13zdmic5t9umH0 Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologists Dr. Mark Tyson from Mayo Clinic Arizona and Dr. Suzanne Merrill from Colorado Urology.---This podcast is supported by:Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/---SYNPOSISThe discussion delves into the newest treatment strategies and FDA-approved therapies for non-muscle invasive bladder cancer with an emphasis on BCG-refractory patients. They highlight their approaches to sequencing therapies, the real-world applicability of these treatments, and the impact of patient factors in clinical decision-making. The panel also explores emerging trials and innovative treatment mechanisms, emphasizing the importance of personalized care in oncology.---TIMESTAMPS00:00 - Introduction05:09 - Challenges and Strategies in Treatment10:55 - Bladder Sparing Therapies21:41 - Practical Tips for Therapy Administration30:39 - Challenges and Considerations in Reinduction37:05 - Clinical Trials and Future Directions44:11 - Counseling Patients on Treatment Options57:36 - Concluding Thoughts and Future Outlook---RESOURCESCORE-008 Clinical Trial https://www.sciencedirect.com/science/article/abs/pii/S1078143924010147Legend Clinical Trial:https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.802CISTO Studyhttps://pubmed.ncbi.nlm.nih.gov/37980511/

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.